monolatrisen

Monolatrisen is a selective serotonin reuptake inhibitor (SSRI) antidepressant medication. It was developed by the pharmaceutical company Lundbeck and was approved for medical use in the European Union in 2019. Monolatrisen is indicated for the treatment of major depressive disorder in adults. It is taken orally and is available in tablet form. The medication works by increasing the levels of serotonin, a neurotransmitter, in the brain, which helps to improve mood and reduce symptoms of depression. Monolatrisen is typically prescribed as an add-on therapy to other antidepressants, as it is believed to have a different mechanism of action that can complement other SSRIs. The recommended starting dose is 20 mg once daily, with the possibility of increasing to 40 mg once daily if necessary. Common side effects of monolatrisen include nausea, diarrhea, and dizziness. Serious side effects are rare but can include suicidal thoughts or behaviors, serotonin syndrome, and an increased risk of bleeding. Monolatrisen should be used with caution in patients with a history of bleeding disorders, as it can increase the risk of bleeding. It is also important to note that monolatrisen should not be used in patients with a history of seizures or in those who are taking monoamine oxidase inhibitors (MAOIs), as this can lead to a potentially life-threatening condition known as serotonin syndrome. Monolatrisen is not approved for use in children, adolescents, or the elderly, and its safety and efficacy in these populations have not been established. It is important to follow the advice of a healthcare professional when considering the use of monolatrisen for the treatment of depression.